GCP
APLS

GSA Capital Partners’s Apellis Pharmaceuticals APLS Stock Holding History

GSA Capital Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-31,446
Closed -$712K – 1655
2025
Q3 		$712K Buy
+31,446
New +$733K 0.06% 611
2025
Q1 		– Sell
-7,835
Closed -$250K – 1627
2024
Q4 		$250K Sell
7,835
-20,749
-73% -$624K 0.02% 1311
2024
Q3 		$824K Buy
+28,584
New +$1.06M 0.06% 592
2022
Q2 		– Sell
-17,303
Closed -$879K – 1377
2022
Q1 		$879K Buy
+17,303
New +$764K 0.12% 230
2021
Q3 		– Sell
-17,447
Closed -$1.1M – 1400
2021
Q2 		$1.1M Buy
17,447
+9,100
+109% +$470K 0.12% 211
2021
Q1 		$358K Buy
8,347
+2,132
+34% +$101K 0.06% 538
2020
Q4 		$355K Sell
6,215
-9,266
-60% -$392K 0.06% 647
2020
Q3 		$467K Buy
+15,481
New +$463K 0.08% 434
2020
Q1 		– Sell
-10,461
Closed -$320K – 1042
2019
Q4 		$320K Buy
+10,461
New +$290K 0.04% 974

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

GSA Capital Partners's APLS Position: Q4 2025 in Review

GSA Capital Partners sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 31,446 shares — an estimated $712K sold.

GSA Capital Partners first reported a position in APLS in Q4 2019 and held it in 9 quarters. The position peaked at $1.1M in Q2 2021. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • GSA Capital Partners reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • GSA Capital Partners sold 31,446 Apellis Pharmaceuticals shares in Q4 2025, an estimated $712K.
  • GSA Capital Partners first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 9 quarters.
  • GSA Capital Partners's Apellis Pharmaceuticals position peaked at $1.1M in Q2 2021.
  • 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.